قيد المعالجة

الرجاء الانتظار...

الإعدادات

الإعدادات

1. WO1997019049 - GLYCINE DERIVATIVES

ملاحظة:نص مبني على العمليات الآلية للتعرف الضوئي على الحروف. الرجاء استخدام إصدار PDF لقيمته القانونية

CLAIMS

1. A compound of formula I


wherein
R is hydrogen, halogen selected from chlorine, bromine, fluorine or iodine, hydroxy,

C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl, C1-C4- haloalkoxy, cyano, nitro, -COOR1 (Rx being as defined below), -CONR3R4 (R3 and R4 independently being hydrogen or C1-C4alkyl), -PO(OR1)2 (R1 being as defined below), -SO3R1 (R1 being as defined below) or -NH-CO-R5 (R5 being C1-C4alkyl or phenyl), R1 and R2, independently, are hydrogen,

C1-C4alkyl or benzyl, and

X is =CH-, =N- or

or a salt thereof.
2. A compound of formula I according to claim 1 wherein R is hydrogen, an halogen selected from chlorine, bromine, fluorine or iodine, hydroxy, C1-C4alkyl, C1- C4alkoxy, C1-C4haloalkyl or C1-C4haloalkoxy, R1 and R2 are hydrogen and X is =CH- or =N- in ortho position to the bond which is linked to the cyclopropyl moiety, or a salt thereof.

3. A compound of claim 1 wherein R is hydrogen or C1- C4alkyl, R1 and R2 are hydrogen and X is =CH-.

4 . The compound of formula



and its salts .

5. A compound of anyone of claims 1 to 4, in free or pharmaceutically acceptable salt form, for use as a pharmaceutical.

6. A compound of anyone of claims 1 to 4, in free or pharmaceutically acceptable salt form, for use in disorders linked to metabotropic glutamate receptors.

7. A compound of anyone of claims 1 to 4, in free or pharmaceutically acceptable salt form, for use in the treatment of cerebral ischemia, head trauma, subarachnoid haemorrage, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, AIDS-induced dementia, Parkinson syndrome, convulsive disorders, muscular spasms, pain, cognitive disorders, schizophrenia, anxiety, emesis and drug abuse.

8. A pharmaceutical composition comprising a compound of anyone of claims 1 to 4 in free or pharmaceutically acceptable salt form, in association with a pharmaceutical carrier or diluent.

9. The use of a compound of anyone of claims 1 to 4 in free or pharmaceutically acceptable salt form, as a pharmaceutical for the treatment of disorders linked to metabotropic glutamate receptors.

10. The use of a compound of anyone of claims 1 to 4 in free or pharmaceutically acceptable salt form, for the manufacture of a medicament for the treatment of disorders linked to metabotropic glutamate receptors.

11. A method for the treatment of disorders linked to metabotropic glutamate receptors in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of anyone of claims 1 to 4 in free or pharmaceutically acceptable salt form.